leisure time -WSS

leisure time

author：hotspot 2025-09-06 08:39:43 - browse：98757

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Scientists successfully use ultrasound imaging to map brain activity

hotspot

entertainment

WSS

Congress: Prevent baby formula shortages by passing a new bill

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

The Bio Revolution is changing business and society

Biohaven protein

Prosthetic arm enables patients to feel the objects they grip

hotspot

leisure time

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Beyond aggravation: Constipation is an American epidemic

Trump demands the U.S. pay no more for drugs than other countries … again

Report: NIH

Affirmative action in medical school literally saved lives

Lab trade group sues FDA to halt regulation of lab

How to save PrEP access — and even expand it

Childbirth

Drug repurposing or repositioning? The language matters

Asahi Kasei to buy Calliditas, picking up kidney disease drug

explore

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Beyond aggravation: Constipation is an American epidemic

Should insurance cover cosmetic surgery?

Dark money group runs ads on China biotech bill

Medical students need to learn the potent medicine of empathy

Addiction doctors spar with methadone clinics over legislation

leisure time

entertainment

Wikipedia

knowledge